38
total announcements
JAGSNPHARM.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹1,438 Cr
P/E (TTM)
32.4
EPS (TTM)
₹6.71
52W Low
₹155.00
52W High
₹264.50
Dividend Yield
1.15%
Beta
-0.27
Price / Book
5.5
Debt / Equity
3.0
Revenue (TTM)
₹294 Cr
Gross Margin
63.90%
Operating Margin
18.36%
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue up 9% YoY, PAT up 22% YoY, and cash reserves at ₹1,700 Mn. The company has also completed the acquisition of a controlling stake in Aequitas Healthcare and concluded a ₹40 crore share buyback.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has announced its Q1 FY27 results, with revenue up 9% YoY, PAT up 22% YoY, and cash reserves at ₹1,700 Mn. The company has also completed the acquisition of a controlling stake in Aequitas Healthcare and concluded a ₹40 crore share buyback.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has announced the record date for the purpose of dividend as 04-Sep-2026, with a recommended dividend of Rs. 4/- (200%) per equity share for the financial year ended March 31, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at its meeting held on July 29, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has scheduled a conference call with analysts and investors on July 30, 2026, to discuss its Q1 FY27 financial results.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the allotment of 94,000 equity shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022) to eligible employees.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals has completed the acquisition of 77.21% equity stake in Aequitas Healthcare Private Limited, as per its proposed acquisition of 85% stake.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the completion of acquisition of 69.77% stake in Aequitas Healthcare Private Limited, making Aequitas a subsidiary of Jagsonpal.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has submitted a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, stating that the promoters have not created any encumbrance over the shares of the company as on March 31, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has announced the acquisition of an 85% stake in Aequitas Healthcare Private Limited, a pharmaceutical company focused on sale and distribution of pharmaceutical products to hospitals, for Rs. 20.8 crores. The acquisition marks Jagsonpal's strategic entry into the hospital segment and is expected to strengthen its presence in India's growing healthcare ecosystem.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals has announced the acquisition of 85% stake in Aequitas Healthcare Private Limited, a pharmaceutical company, for INR 20.8 Crore. The acquisition is expected to be completed by 15th July 2026 and is aimed at gaining access to the hospital channel and institutional doctor network for the Company’s products.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited will remain closed for Designated Persons and their immediate relative(s) from July 01, 2026, and will open 48 hours after the declaration of unaudited financial results for the quarter ended on June 30, 2026.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has appointed Mr. Anil Kumar Matai as an Independent Director on its Board, bringing over three decades of experience in the pharmaceutical and healthcare sectors.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange about the appointment of Mr. Anil Kumar Matai as an Independent Director, effective June 25, 2026, for a period of 5 years, subject to shareholder approval.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has appointed Mr. Anil Kumar Matai as an Independent Director, effective June 25, 2026, for a period of 5 years, subject to shareholder approval.
Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the appointment of Mr. Anil Kumar Matai as a Non-Executive Independent Director of the company, effective June 25, 2026.